Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| G1 Therapeutics, Inc.GTHX · Entity 87413 | CFO | January 03, 2023 | January 05, 2023 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
G1 Therapeutics, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,188 |
Reported balance
After 2023-01-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 22,300 · Balance 60,188 F1: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. F2: Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Represents (i) 19,013 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 58,549 |
Reported balance
After 2023-01-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-01-04 · Sale · Disposed 1,639 · Balance 58,549 F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F5: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: Represents (i) 20,374 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 57,820 |
Reported balance
After 2023-01-05 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-01-05 · Sale · Disposed 729 · Balance 57,820 F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. F7: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8: Represents (i) 21,020 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 · Expires 2033-01-03 | Direct | 44,600 |
Reported balance
After 2023-01-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-03 · Grant · Acquired 44,600 · Balance 44,600 F9: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2: Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Represents (i) 19,013 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 12,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023.
F4: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5: The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: Represents (i) 20,374 shares of common stock; (ii) 6,875 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023.
F7: The price represents the weighted average price with a low of $5.35 and a high of $5.49. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: Represents (i) 21,020 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 22,300 RSUs from award granted on January 3, 2023.
F9: The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
Viridian Therapeutics, Inc.\DE
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2036-07-01 | Direct | 32,341 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 32,341 · Balance 32,341 F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2018 Filed Aug 6, 2018 18:18 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-003499 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 15:21 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-003237 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 750 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 15:21 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $45.66 | $34,245.00 |
DisclosureSEC source: 0001562180-18-003237 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 15:21 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-003237 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 14:23 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 500 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-002856 · primarydocument.xml · derivative · entry 4 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock · 500 shares Expires 2024-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 14:23 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 250 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-002856 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 14:23 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $38.77 | $29,077.50 |
DisclosureSEC source: 0001562180-18-002856 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 14:23 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-002856 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 07, 2018 Filed May 7, 2018 15:04 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-002313 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 750 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 07, 2018 Filed May 7, 2018 15:04 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $45.00 | $33,750.00 |
DisclosureSEC source: 0001562180-18-002313 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 07, 2018 Filed May 7, 2018 15:04 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-002313 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 05, 2018 Filed Apr 5, 2018 16:04 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-001868 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 750 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| April 05, 2018 Filed Apr 5, 2018 16:04 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $37.47 | $28,102.50 |
DisclosureSEC source: 0001562180-18-001868 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 05, 2018 Filed Apr 5, 2018 16:04 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-001868 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 16:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-001485 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 750 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 16:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $26.55 | $19,912.50 |
DisclosureSEC source: 0001562180-18-001485 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 16:01 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-001485 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 11:00 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-000626 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 750 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 11:00 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $22.99 | $17,242.50 |
DisclosureSEC source: 0001562180-18-000626 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 11:00 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-000626 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 09:42 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionStock Options (Right to Buy) · Derivative | 750 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001562180-18-000248 · primarydocument.xml · derivative · entry 3 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 750 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 09:42 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | SaleCommon Stock | 750 | $19.96 | $14,970.00 |
DisclosureSEC source: 0001562180-18-000248 · primarydocument.xml · nonDerivative · entry 2 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 09:42 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Exercise / conversionCommon Stock | 750 | $0.39 | $292.50 |
DisclosureSEC source: 0001562180-18-000248 · primarydocument.xml · nonDerivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 09:40 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.49 | $0.00 |
DisclosureSEC source: 0001562180-18-000171 · primarydocument.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-01-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% of the shares on January 02, 2019, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.